ALMA MATER STUDIORUM
UNIVERSITÀ DI BOLOGNA

DIPARTIMENTO
DI FARMACIA
E BIOTECNOLOGIE

AVVISO DI SEMINARIO

Il giorno **27 maggio 2025**
alle ore **10:00**

Dr. Alberto Calabrò

Patient Access Program & Supply Lead, Roche
(ospite del Prof. Francesco Musiani)

terrà un seminario in lingua inglese dal titolo:

Understanding Compassionate Use Programs

How Managed Access Programs transform patient lives

Area tematica:
Cancer Biology; Drug discovery and development

in presenza:
Aula Magna ANATOMIA OLIVO, Via Irnerio 48, Bologna BO

e in streaming:
https://teams.microsoft.com/l/meetup-join/19%3aN09c0NIyEssBnF7ObCyDOQwkgDWm1qdd9f7F2nJV9fw1%40thread.tacv2/1631519544944?context=%7b%22Tid%22%3a%22e99647dc-1b08-454a-bf8c-699181b389ab%22%2c%22Oid%22%3a%225a941351-ef41-4aa4-8771-fa50a6d62ca1%22%7d

Colleghi e studenti sono cordialmente invitati

ABSTRACT

Have you ever wondered what happens when patients need access to potentially life-saving treatments that are still in clinical development? How do clinicians and pharmaceutical companies navigate the complex landscape of clinical research to provide these treatments ethically and responsibly? These compelling questions form the basis of our discussion on Managed Access Programs (MAPs) and Compassionate Use Programs (CUPs).
Dr. Alberto Calabrò, an expert with extensive experience spanning basic research, clinical research, and managed access programs, will share insights from his role as the Patient Access Program & Supply Lead at Roche, Basel. In this presentation, we will explore the essential mechanisms underlying MAPs and CUPs, illustrating how they provide critically ill patients with early access to investigational therapies outside of clinical trials.
Through real-world examples and case studies, Dr. Calabrò will highlight the collaborative efforts needed between pharmaceutical companies, regulatory bodies, healthcare professionals, and patients to ensure the ethical and effective implementation of these programs. Attendees will gain an understanding of the regulatory landscape, the importance of patient support, and the practical challenges involved in managing drug supply and compliance within MAPs and CUPs.
Join us in this exploration of how Managed Access Programs serve as a bridge between clinical research and patient care, potentially transforming the lives of patients who have exhausted other treatment options. This session aims to inspire university students by demonstrating the significant impact that compassionate use and early access initiatives can have on patient outcomes and the overall advancement of medical science.

BIOGRAPHICAL SKETCH

Dr. Alberto Calabrò is a dedicated professional with a career spanning basic research, clinical research, and managed access programs, all aimed at improving patient outcomes. He holds a Master's degree (M.Sc.) in Medical Biotechnology from the University of Bologna and a PhD in Tumor Biology from the University of Heidelberg. His research has led to multiple publications and presentations at international conferences, underscoring his commitment to advancing medical knowledge.
In his current role as the Patient Access Program & Supply Lead at Roche in Basel, Switzerland, Dr. Calabrò coordinates Early Access Programs and manages Compassionate Use (CU) programs. He played a key role in establishing a global tool for tracking and managing compassionate use requests. His expertise in regulatory compliance and patient support has been pivotal to his success at Roche.
Before joining Roche, Dr. Calabrò gained valuable experience as a Clinical Research Associate (CRA) at Pharmaceutical Product Development (PPD). There, he facilitated communication between investigative sites and sponsors, identified potential investigators, and ensured regulatory compliance.